



Sylentis presents new results on its ophthalmological compounds at ARVO 2018

- The Company presents the preclinical and clinical results from studies of three molecules for the treatment of dry eye syndrome, macular degeneration and eye allergies.
- The presentation will take place in the framework of the annual meeting of the Association for Research in Vision and Ophthalmology (ARVO). That will be held from the 29th of April to the 3rd of May in Honolulu, Hawaii.

Madrid, April 26th, 2018. Sylentis, Pharmaceutical Company belonging to PharmaMar Group will present new results on three ophthalmological compounds for the treatment of dry eye syndrome, macular degeneration associated to age, administered topically, and also for the treatment of eye allergies. The mentioned presentations will take place under the framework of the annual meeting of the Association for Research in Vision and Ophthalmology (ARVO) that will be held from the 29th of April up to the 3rd of May in Honolulu, Hawaii.

It comprises of various sessions, to where approximately 11,000 researchers and ophthalmologists attend every year to share the latest research developments in the field of ophthalmology, and which will contribute to a progress in the knowledge of both basic science and cutting edge treatments.

According to Ana Isabel Jiménez, Director of R&D at Sylentis, *"we are proud to present our results to the first rate audience that is attending this meeting. We trust in our technology to become a real alternative for the treatment of millions of people that suffer from these types of illnesses in the future."*

In fact, Jiménez highlights that *"currently, the line of work where we have progressed fastest is in ophthalmology, for the treatment of illnesses such as dry eye syndrome, allergies and retinal diseases."*

Sylentis, expert in the research of new treatments for ophthalmological and inflammatory illnesses, is a company leader in RNAi technology and it is one of the few companies in Europe that apply this technology to the field of ophthalmology.

The studies presented during this congress are available at <https://www.arvo.org/annual-meeting/program/online-planner/>

Studies to be presented by Sylentis at ARVO 2018:

- **Tivanisiran, a new treatment for Dry Eye Disease, that improved signs and symptoms in clinical trials (Posterboard number: 925 - B0103)**
Session: 29th April from 15:15 to 17:00 hours. Lead author: Ana Isabel Jiménez et al. R&D, Sylentis, Spain.

- **Topical administration of siRNA targeting NRARP as a new treatment for choroidal neovascularization (Posterboard Number: 2634 - A0139)**
Session: 1st of May from 8:15 to 10:00 hours. Lead author: Verónica Ruz, et al. Regulatory Affairs, Sylentis, Spain.
- **Development of a RNAi therapeutic for the treatment of allergic conjunctivitis (Posterboard Number: 5567 - A0259)**
Session: 3rd May, from 8:15 to 10:00 hours. Lead author: Victoria González et al. Clinical Department, Sylentis, Spain.

What is RNA interference? <https://www.youtube.com/watch?v=iXvSitR5184>

About Sylentis

Sylentis, a company of PharmaMar (MSE:PHM), is a biotechnology company fully owned that develops innovative therapies harnessing the technology of post-transcriptional gene silencing or RNA interference (RNAi). Sylentis has developed an approach to efficiently design RNAi-based therapeutics that can be used to silence numerous disease-causing genes. We currently have a robust therapeutic program in ophthalmology with two candidates under development in Phase II and III studies for glaucoma (bamosiran)ⁱ and ocular pain (SYL1001)ⁱⁱ, respectively. Sylentis is also developing new products for the treatment of several eye diseases such as ocular allergies and retina diseases. To know more about us, please visit us at www.sylentis.com.

Disclaimer

This document is a press release, not a prospectus. This document does not constitute or form part of an offering or invitation to sell or a solicitation to purchase, offer or subscribe shares of the company. Moreover, no reliance should be placed upon this document for any investment decision or contract and it does not constitute a recommendation of any type with regard to the shares of the company.

For more information:

Alfonso Ortín – Communications Director aortin@pharmamar.com Móvil : + 34609493127
Paula Fernández – Media Relations Manager pfalarcon@pharmamar.com Móvil: +34 638796215
Teléfono: +34 918466000

Investors:

Teléfono: +34 914444500 o visite www.sylentis.com y www.pharmamar.com

ⁱ Moreno-Montañes J, Sádaba B, Ruz V, Gomez-Guiu A, Zarranz J, Gonzalez MV, Pañeda C, Jimenez AI. Phase I Clinical Trial of SYL040012, A Small Interfering RNA Targeting β -Adrenergic Receptor 2, for Lowering Intraocular Pressure. Mol Ther. 2014, 22(1):226-32

ⁱⁱ <https://clinicaltrials.gov/ct2/show/NCT03108664?term=helix&rank=5> (April, 2018)